Biologics Market Growth To Be Driven By Increased Understanding Of The Genetic & Molecular Basis Of A Disease Till 2025:Grand View Research,inc.
The global biologics market is anticipated to reach USD 399.5
billion by 2025, according to a new report by Grand View Research, Inc.
Introduction of targeted therapies coupled with rising adoption of patient
centric personalized medicine anticipated to fuel demand. Ever-increasing understanding
of the cell physiology and stress, as well as the factors involved in protein
production and heterologous gene expression have empowered the use of different
living factories.
These living factories are the
prokaryotic and eukaryotic cells. Enhancement of drug functionality through
achieving successful protein folding and post-translational modifications is
supportive for projected progress rate.
Moreover, rising adoption of
biopharmaceuticals over chemically synthesized molecules is expected to propel
revenue generation significantly. In addition to this, presence of several
metabolic disorders that can be treated through the use of biologics is
attributive to influence demand.
Combination of advanced
bioengineering technologies for biopharmaceutical production is expected to
boost progress in pharmaceutical industry. With recent advances in automation,
the selection process can be done through high throughput screening (HTS)
system for selection of viable clones.
Aforementioned method enables robust
production of biopharmaceutical products by obtaining high-producing cell line.
Advances with respect to upstream and downstream processing would directly
translate into the growth in revenue for this market at a larger level.
However, development of
biosimilars is expected to restrain the biologics year on year growth to
certain extent. Although, the regulatory approval pathway for these products is
not framed yet some drug manufacturers are opting to invest in the development of
biobetters.
Browse full research report on Biologics Market: http://www.grandviewresearch.com/industry-analysis/biologics-market
Further key findings from
the report suggest:
- Microbial expression systems dominated the market
with respect to biopharmaceutical manufacturing
- Presence of substantial number of products
manufactured through the use of microbial sources can be attributed for
largest share
- Higher usage of monoclonal antibodies for the
treatment of different diseases responsible for revenue generation
- Moreover, pipeline drugs in the phase of development
anticipated to bolster growth
- Significant development pertaining to vaccines and
increasing adoption anticipated to fuel progress
- Oncology dominated over a decade and is expected to
sustain its share over the forecast period.
- Introduction of novel biologics with high efficacy
coupled with the augmenting incidences of cancer is the vital impact
rendering factor.
- Substantial sales of biologics in the U.S. can be
attributed for the largest share of North American market.
- Established participants are implementing the
manufacture of complex moieties in-house, which pronounces for the larger
share of in-house manufacturing.
- Asia Pacific is projected to showcase fastest growth
in the coming years.
- Increasing penetration of the biologics in the
developing economies is expected to contribute in the projected growth.
- Moreover, the university based projects implemented
herein are attributive for the projected growth.
- Key players contributing in this market are F
Hoffman La Roche, Samsung Biologics, Celltrion, Pfizer Inc., Amgen,
Novo Nordisk A/S, Sanofi, Abbvie Inc., Merck & Co. Inc, Addgene,
Johnson & Johnson Services Inc., and Eli Lilly & Company.
- These participants are investing in the hybrid
business models through providing technology and service platforms.
- Such milestones and royalties from partnered programs
enables the cash flow generation which can be utilized in proprietary
R&D.
Browse more reports of this category by Grand View
Research: http://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the biologics market on
the basis of source, product, manufacturing, disease category, and region:
Biologics Source Outlook (Revenue, USD Billion, 2014 -
2025)
- Microbial
- Mammalian
- Others
Biologics Product Outlook (Revenue, USD Billion, 2014 -
2025)
- Monoclonal
Antibodies
- By
application
- Diagnostic
- Biochemical
Analysis
- Diagnostic
Imaging
- Therapeutic
- Direct
MAB Agents
- Targeting
MAB Agents
- Protein
Purification
- Others
- By
type
- Murine
- Chimeric
- Humanized
- Human
- Others
- Vaccines
- Recombinant
Proteins
- Antisense,
RNAi, & Molecular Therapy
- Others
Biologics Manufacturing Outlook (Revenue, USD Billion,
2014 - 2025)
- In-house
- Outsourced
Biologics Disease Category Outlook (Revenue, USD Billion,
2014 - 2025)
- Oncology
- By
Product
- MABs
- Vaccines
- Recombinant
Proteins
- Antisense,
RNAi, & Molecular Therapy
- Others
(Certain products under trials related to blood products etc)
- Infectious
Diseases
- By
Product
- Vaccines
- MABs
- Antisense,
RNAi, & Molecular Therapy
- Recombinant
Proteins
- Others
- Immunological
Disorders
- Cardiovascular
Disorders
- Hematological
Disorders
- Others
Biologics Regional Outlook (Revenue, USD Billion, 2014 -
2025)
- North
America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia
Pacific
- Japan
- China
- Latin
America
- Brazil
- Middle
East and Africa (MEA)
- South
Africa
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
Comments
Post a Comment